Starling Oncology, Inc. (STLNW) Operating cash flow 2020–2025
Starling Oncology, Inc. (STLNW) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$24.6MFY2025 · since FY2020: $508,000 → -$24.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$24.6M | +7.4% |
| FY2024 | -$26.5M | +26.9% |
| FY2023 | -$36.3M | +41.2% |
| FY2022 | -$61.8M | -89.0% |
| FY2021 | -$32.7M | -6533.1% |
| FY2020 | $508,000 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More STLNW financial trends
STLNW RevenueSTLNW Net incomeSTLNW Net marginSTLNW Gross profitSTLNW Gross marginSTLNW Operating incomeSTLNW Operating marginSTLNW Free cash flowSTLNW Capital expendituresSTLNW Return on equitySTLNW Stock buybacksSTLNW Dividends paidSTLNW Total assetsSTLNW Total liabilitiesSTLNW Shareholders’ equitySTLNW overview →